• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Value Assessment Frameworks Should Represent a Spectrum of Patient Preferences

Video

Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow, discusses what needs to be included in the next generation of value assessment frameworks in order to best identify value that is representative of all patient preferences.

Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Center’s Postdoctoral Health Policy Fellow, discusses what needs to be included in the next generation of value assessment frameworks in order to best identify value that is representative of all patient preferences.

Transcript (slightly modified)

What would you like to see included in the next generation of value assessment frameworks to better identify value?

In the next generation of value assessment frameworks, we need to make sure that they are able to account for patient preference in a way that the patient and the physician can understand what is the value of a therapy given a patient’s specific set of preferences. To do this, we need to do a few things. First, we need to think about preferences much earlier in the development process. This way we can make sure that therapies are developed with patient preferences in mind, and then the clinical outcomes that are designed to measure the efficacy of those therapies are the outcomes that matter to patients.

Once we have those outcomes, patient preferences need to be incorporated into the actual value assessment and then, finally, the value assessment must offer a range of values to represent the spectrum of patient preferences.

Related Videos
Shawn Kwatra, MD, dermatologist, John Hopkins University
Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients with Plaque Psoriasis
dr krystyn van vliet
Martin Dahl, PhD, senior vice president, AnaptysBio
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Jonathan Silverberg, MD, PhD, MPH, FAAD, professor of dermatology, director of clinical research and patch testing, George Washington University School of Medicine and Health Sciences
Monica Li, MD, University of British Columbia
Robert Sidbury, MD, MPH, FAAD, professor of pediatrics, division head of dermatology, Seattle Children's Hospital, University of Washington School of Medicine
Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University Chicago Medical School, founder and director of the Center for Medical Dermatology and Immunology Research
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.